Inhibition of Hexokinase-2 with Targeted Liposomal 3-bromopyruvate in an Ovarian Tumor Spheroid Model of Aerobic Glycolysis

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2015 Jul 18

PMID 26185443

Citations 18

Authors

Srujan Kumar Gandham

Meghna Talekar

Amit Singh

Mansoor M Amiji

Affiliations

Soon will be listed here.

Abstract

Background: The objective of this study was to evaluate the expression levels of glycolytic markers, especially hexokinase-2 (HK2), using a three-dimensional multicellular spheroid model of human ovarian adenocarcinoma (SKOV-3) cells and to develop an epidermal growth factor receptor-targeted liposomal formulation for improving inhibition of HK2 and the cytotoxicity of 3-bromopyruvate (3-BPA).

Methods: Multicellular SKOV-3 tumor spheroids were developed using the hanging drop method and expression levels of glycolytic markers were examined. Non-targeted and epidermal growth factor receptor-targeted liposomal formulations of 3-BPA were formulated and characterized. Permeability and cellular uptake of the liposomal formulations in three-dimensional SKOV-3 spheroids was evaluated using confocal microscopy. The cytotoxicity and HK2 inhibition potential of solution form of 3-BPA was compared to the corresponding liposomal formulation by using cell proliferation and HK2 enzymatic assays.

Results: SKOV-3 spheroids were reproducibly developed using the 96-well hanging drop method, with an average size of 900 µm by day 5. HK2 enzyme activity levels under hypoxic conditions were found to be higher than under normoxic conditions (P<0.0001, Student's t-test, unpaired and two-tailed). Liposomal formulations (both non-targeted and targeted) of 3-BPA showed a more potent inhibitory effect (P<0.001, Student's t-test, unpaired and two-tailed) at a dose of 50 µM than the aqueous solution form at 3, 6, and 24 hours post administration. Similarly, the cytotoxic activity 3-BPA at various concentrations (10 µM-100 µM) showed that the liposomal formulations had an enhanced cytotoxic effect of 2-5-fold (P<0.0001, Student's t-test, unpaired and two-tailed) when compared to the aqueous solution form for both 10 µM and 25 µM concentrations.

Conclusion: SKOV-3 spheroids developed by the hanging drop method can be used as a tumor aerobic glycolysis model for evaluation of therapies targeting the glycolytic pathway in cancer cells. Encapsulation of 3-BPA in a liposomal formulation improved permeability, HK2 inhibition, and cytotoxicity in the multicellular spheroid model.

Citing Articles

Multimodal Imaging of Pancreatic Cancer Microenvironment in Response to an Antiglycolytic Drug.

Sheikh E, Agrawal K, Roy S, Burk D, Donnarumma F, Ko Y Adv Healthc Mater. 2023; 12(31):e2301815.

PMID: 37706285 PMC: 10842640. DOI: 10.1002/adhm.202301815.

Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties.

Mahdavi Firouzabadi B, Gigliobianco M, Joseph J, Censi R, Di Martino P Pharmaceutics. 2022; 14(12).

PMID: 36559202 PMC: 9785496. DOI: 10.3390/pharmaceutics14122708.

PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer.

Karim S, Burzangi A, Ahmad A, Siddiqui N, Ibrahim I, Sharma P Int J Mol Sci. 2022; 23(4).

PMID: 35216429 PMC: 8880628. DOI: 10.3390/ijms23042305.

Mitochondria-targeted nanoplatforms for enhanced photodynamic therapy against hypoxia tumor.

Wen J, Luo Y, Gao H, Zhang L, Wang X, Huang J J Nanobiotechnology. 2021; 19(1):440.

PMID: 34930284 PMC: 8686264. DOI: 10.1186/s12951-021-01196-6.

CircHIPK3/miR-381-3p axis modulates proliferation, migration, and glycolysis of lung cancer cells by regulating the AKT/mTOR signaling pathway.

Gu F, Zhang J, Yan L, Li D Open Life Sci. 2021; 15(1):683-695.

PMID: 33817257 PMC: 7747506. DOI: 10.1515/biol-2020-0070.

References

Haycock J . 3D cell culture: a review of current approaches and techniques. Methods Mol Biol. 2010; 695:1-15. DOI: 10.1007/978-1-60761-984-0_1. View

Alexis F, Pridgen E, Langer R, Farokhzad O . Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010; (197):55-86. DOI: 10.1007/978-3-642-00477-3_2. View

Guarneri V, Piacentini F, Barbieri E, Conte P . Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010; 117(2):152-8. DOI: 10.1016/j.ygyno.2009.11.033. View

Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H . ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008; 320(5876):661-4. DOI: 10.1126/science.1156906. View

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

Da Silva A, El-Bacha T, Kyaw N, Dos Santos R, da-Silva W, Almeida F . Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J. 2008; 417(3):717-26. DOI: 10.1042/BJ20080805. View

Patra K, Wang Q, Bhaskar P, Miller L, Wang Z, Wheaton W . Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013; 24(2):213-228. PMC: 3753022. DOI: 10.1016/j.ccr.2013.06.014. View

Fennema E, Rivron N, Rouwkema J, van Blitterswijk C, de Boer J . Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol. 2013; 31(2):108-15. DOI: 10.1016/j.tibtech.2012.12.003. View

Shoshan M . 3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr. 2012; 44(1):7-15. DOI: 10.1007/s10863-012-9419-2. View

10.

Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J . Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005; 19(14):1978-85. DOI: 10.1096/fj.05-4058com. View

11.

Xu X, Khan M, Burgess D . A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm. 2011; 423(2):543-53. DOI: 10.1016/j.ijpharm.2011.11.036. View

12.

Mendelsohn J, Baselga J . Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006; 33(4):369-85. DOI: 10.1053/j.seminoncol.2006.04.003. View

13.

Mathupala S, Rempel A, Pedersen P . Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem. 2001; 276(46):43407-12. DOI: 10.1074/jbc.M108181200. View

14.

Magadala P, Amiji M . Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 2008; 10(4):565-76. PMC: 2628214. DOI: 10.1208/s12248-008-9065-0. View

15.

Kostarelos K, Emfietzoglou D, Papakostas A, Yang W, Ballangrud A, Sgouros G . Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer. 2004; 112(4):713-21. DOI: 10.1002/ijc.20457. View

16.

Friedrich J, Seidel C, Ebner R, Kunz-Schughart L . Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009; 4(3):309-24. DOI: 10.1038/nprot.2008.226. View

17.

Wenning L, Murphy R . Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol Bioeng. 1999; 62(5):562-75. View

18.

Bangham A . Liposomes: the Babraham connection. Chem Phys Lipids. 1993; 64(1-3):275-85. DOI: 10.1016/0009-3084(93)90071-a. View

19.

Chang T, Hughes-Fulford M . Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng Part A. 2008; 15(3):559-67. PMC: 6468949. DOI: 10.1089/ten.tea.2007.0434. View

20.

Ward J, King J . Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures. Math Biosci. 2002; 181(2):177-207. DOI: 10.1016/s0025-5564(02)00148-7. View